Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HHS Stock Forecast 2025-2026
$3.21
Current Price
$23.80M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to HHS Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
HHS Price Momentum
-14.9%
1 Week Change
+15.9%
1 Month Change
-45.9%
1 Year Change
-37.7%
Year-to-Date Change
-48.3%
From 52W High of $6.20
+37.6%
From 52W Low of $2.33
📊 TOP ANALYST CALLS
Did HHS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Harte-Hanks is one of their latest high-conviction picks.
Latest HHS Stock Price Targets & Analyst Predictions
HHS has shown a year-to-date change of -37.7% and a 1-year change of -45.9%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for HHS. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HHS Analyst Ratings
1
Buy
0
Hold
0
Sell
HHS Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $3.21
Latest HHS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HHS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 9, 2017 | Noble Capital Markets | Michael Kupinski | Buy | Upgrade | $N/A |
| Mar 14, 2016 | BMO Capital | Market Perform | Downgrade | $N/A | |
| Dec 8, 2015 | Singular Research | Buy | Initiates | $5.00 | |
| Jul 21, 2015 | BMO Capital | Outperform | Upgrade | $N/A | |
| May 30, 2014 | BMO Capital | Market Perform | Downgrade | $N/A | |
| Oct 21, 2013 | Noble Capital Markets | Michael Kupinski | Hold | Downgrade | $12.00 |
| Oct 4, 2013 | BMO Capital | Outperform | Upgrade | $N/A | |
| Apr 26, 2013 | Noble Capital Markets | Buy | Upgrade | $N/A | |
| Feb 1, 2013 | BMO Capital | Market Perform | Maintains | $N/A | |
| Feb 1, 2013 | Noble Capital Markets | Michael Kupinski | Hold | Downgrade | $7.00 |
| Oct 26, 2012 | Noble Capital Markets | Michael Kupinski | Buy | Upgrade | $N/A |
| Oct 26, 2012 | BMO Capital | Market Perform | Maintains | $N/A | |
| Jul 18, 2012 | Noble Capital Markets | Michael Kupinski | Hold | Downgrade | $N/A |
Harte-Hanks Inc. (HHS) Competitors
The following stocks are similar to Harte-Hanks based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Harte-Hanks Inc. (HHS) Financial Data
Harte-Hanks Inc. has a market capitalization of $23.80M with a P/E ratio of 2.3x. The company generates $166.84M in trailing twelve-month revenue with a -3.3% profit margin.
Revenue growth is -17.0% quarter-over-quarter, while maintaining an operating margin of +1.9% and return on equity of -26.6%.
Valuation Metrics
Market Cap
$23.80M
Enterprise Value
$39.02M
P/E Ratio
2.3x
PEG Ratio
0.0x
Price/Sales
0.1x
Growth & Margins
Revenue Growth (YoY)
-17.0%
Gross Margin
+70.3%
Operating Margin
+1.9%
Net Margin
-3.3%
EPS Growth
-17.0%
Financial Health
Cash/Price Ratio
+27.4%
Current Ratio
1.5x
Debt/Equity
109.5x
ROE
-26.6%
ROA
+1.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Harte-Hanks Inc. (HHS) Business Model
About Harte-Hanks Inc.
What They Do
Provides multi-channel marketing solutions and services.
Business Model
Harte-Hanks generates revenue by offering integrated marketing services that combine traditional and digital channels. It focuses on data management, analytics, and customer care to enhance client engagement and brand performance across various industries, including retail and healthcare.
Additional Information
With a significant role in marketing transformation, Harte-Hanks empowers businesses with actionable intelligence, making it a valuable partner in a competitive marketplace. The company is headquartered in the United States and continues to leverage its expertise to innovate within the marketing services sector.
Company Information
Sector
Industrials
Industry
Conglomerates
Employees
2,200
CEO
Mr. Kirk A. Davis
Country
United States
IPO Year
1993
Website
www.hartehanks.comHarte-Hanks Inc. (HHS) Latest News & Analysis
Latest News
Harte Hanks Reports Third Quarter 2025 Results
27 days ago
Quick Summary
Harte Hanks, Inc. reported Q3 2025 revenue of $39.5 million, down from $47.6 million in Q3 2024, citing timing and program transitions. The company also announced a new partnership with Samsung.
Why It Matters
The revenue decline suggests potential challenges, but the new Samsung partnership indicates growth opportunities and pipeline strength, influencing future performance and investor sentiment.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Harte Hanks (NASDAQ:HHS) opened a new Customer Care center in Greenville, SC, in partnership with Samsung, creating over 150 local jobs.
Why It Matters
Harte Hanks' new Customer Care center with Samsung expands its operations and job creation, signaling growth potential and partnership strength, which could positively impact stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Harte Hanks (HHS) Q2 Revenue Falls 14%
3 months ago
Quick Summary
Harte Hanks (HHS) reported a 14% decline in revenue for Q2.
Why It Matters
Harte Hanks' 14% revenue decline may signal weakening demand or operational challenges, potentially impacting profitability and stock performance, raising concerns for shareholders.
Source: The Motley Fool
Market Sentiment:
Neutral
Harte Hanks Reports Second Quarter 2025 Results
4 months ago
Quick Summary
Harte Hanks, Inc. reported positive EBITDA for Q2 2025, maintained a debt-free balance sheet, and showed a strong cash position despite revenue challenges.
Why It Matters
Harte Hanks' positive EBITDA and debt-free status indicate financial stability, attracting investors seeking reliable returns despite revenue challenges.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Harte Hanks, Inc. has extended its $25 million revolving credit line with Texas Capital Bank to June 2028, enhancing financial flexibility and supporting long-term stability.
Why It Matters
Harte Hanks' extended credit facility enhances liquidity and operational stability, signaling financial health and potential for growth, which can positively influence investor confidence and stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Harte Hanks, Inc. Appoints David Fisher as President to Lead Next Phase of Client Innovation and Growth
5 months ago
Quick Summary
Harte Hanks appointed David Fisher as President to lead innovation and client-centric growth, focusing on transformation and sustained EBITDA growth.
Why It Matters
David Fisher's appointment signals a focus on innovation and efficiency at Harte Hanks, potentially enhancing client value and driving EBITDA growth, which could positively impact stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About HHS Stock
What is Harte-Hanks Inc.'s (HHS) stock forecast for 2026?
Analyst forecasts for Harte-Hanks Inc. (HHS) are not currently available. The stock is trading at $3.21.
Is HHS stock a good investment in 2026?
According to current analyst ratings, HHS has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.21. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HHS stock?
Price predictions from Wall Street analysts for HHS are not currently available. The stock is trading at $3.21.
What is Harte-Hanks Inc.'s business model?
Harte-Hanks generates revenue by offering integrated marketing services that combine traditional and digital channels. It focuses on data management, analytics, and customer care to enhance client engagement and brand performance across various industries, including retail and healthcare.
What is the highest forecasted price for HHS Harte-Hanks Inc.?
Price targets from Wall Street analysts for HHS are not currently available. The stock is trading at $3.21.
What is the lowest forecasted price for HHS Harte-Hanks Inc.?
Price targets from Wall Street analysts for HHS are not currently available. The stock is trading at $3.21.
What is the overall HHS consensus from analysts for Harte-Hanks Inc.?
The overall analyst consensus for HHS is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are HHS stock price projections?
Stock price projections, including those for Harte-Hanks Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 4:49 PM UTC